Warhound Launches $200 Million Push to Clone Superior Service Dogs

The world of military technology is seeing a significant shift as a new startup named Warhound secures a major financial backing. The company has raised $200 million to develop a specific line of genetically engineered dogs for the US military. This initiative represents a joint effort between two prominent figures in the tech and science sectors. Ben Lamm, who is known for his work with Colossal Biosciences, and Palmer Luckey, the founder of Anduril, are leading this venture together.

Work on the biological side of the project has already begun. Lamm noted that scientists have started editing genes from cell samples taken from a first group of donor dogs. These donors are not random pets. They are top-performing animals currently serving with military, police, and first responder units across the United States. The group primarily consists of Belgian Malinois, with some labradors and shepherds included in the mix. The scientific team at Colossal plans to modify these genes and then use cloning techniques to produce new animals.

The initial focus of this research is practical and health-oriented. The goal is to lower the likelihood that these dogs develop common health issues associated with their specific breeds. Hip dysplasia and certain types of cancer are among the conditions scientists hope to address through genetic modification. Lamm suggested that further enhancements could follow this initial phase. Future genetic changes might be designed to make the animals faster, more agile, or equipped with a sharper sense of smell.

The leadership behind Warhound brings significant experience to the table. Luckey is best known for founding Oculus VR and designing the Oculus Rift headset. His defense company, Anduril, has established a strong presence in military technology. In 2024, Anduril partnered with OpenAI to develop artificial intelligence solutions for the Pentagon. More recently, the company won a contract with the US Army to build the service's next-generation battlefield intelligence system, working alongside Palantir.

Lamm's background is equally notable in the field of biotechnology. Colossal Biosciences has been involved in several high-profile de-extinction projects. One effort claims to have revived the dire wolf, while another seeks to bring back the woolly mammoth. This track record of working with complex biological systems provides a foundation for the genetic work now underway at Warhound.

While the biology is handled by Colossal, Anduril's role is focused on equipment rather than the animals themselves. Warhound does not appear to be planning to create cyborg dogs, at least for the time being. Instead, Anduril will design the tools and the software that runs them. These technologies are intended to protect the animals while they perform their duties. Examples of this gear include specialized goggles, vests, and body armor.

The ownership structure of the new company is distinct from its public profile. Although Luckey is a partner in the business, neither he nor Anduril holds a direct stake in the startup. Colossal Biosciences does have equity in the company, and Lamm sits on the board of directors. David Spirk, who most recently worked at Palantir, has been named as the CEO. This structure suggests a clear division of labor between the biological and technological components of the project.

The timeline for seeing results is set for the near future. Warhound expects the first batch of its genetically engineered dogs to be born in early 2027. Once born, these animals will undergo training for the same kinds of jobs that current working dogs perform. This includes detecting bombs and assisting in search-and-rescue operations. The project aims to combine biological optimization with high-tech protection to enhance the capabilities of military working dogs.